We conducted 2 base-case analyses to represent the situation of typical persons faced with the decision of whether to receive the influenza vaccine.
In the base case analyses of these studies, cost-effectiveness results ranged from dominated to dominant.
It is interesting to note that when treatment was added as a covariate to the survival models, the results pertaining to black race were consistent with those in the base case analyses, except that the coefficients were smaller in the models that included treatment.
According to these base case analyses, the incremental total cost difference of erlotinib vs docetaxel amounts to −€1577.
The majority of one-way sensitivity analyses did not substantially impact the ICERs compared to the base case analyses.
For our base case analyses, a hypothetical alcohol intervention was assumed to decrease unhealthy alcohol consumption by 45%.
In base case analyses, we considered only the direct benefit to the boys vaccinated, which does not depend on vaccine uptake in other men.
We performed threshold analyses on the proportion of chemotherapy-treated women classified as being in the intermediate risk group by the RS-assay, on the risk of relapse in the RS-assay model and other parameters found to influence our base case analyses (Tables 4 and 5).
All base case analyses will be performed based on the 'intention to treat' principle.
These analyses were carried out using the base probability and utility values in the model, with the incidence of SCID among newborns set to 0. Outcomes measured in base case analyses were the number of TB cases occurring (meningeal, miliary, and other), and quality-adjusted life years (QALYs) in each cohort.
Our base case analyses utilized 70% specificity cutoffs, as higher-specificity cutoffs are thought to be cost-effective (5).
